BR 6819

Drug Profile

BR 6819

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer
  • Class Cardiovascular therapies
  • Mechanism of Action Vasopressin 1a receptor antagonists; Vasopressin V2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Heart failure

Most Recent Events

  • 11 Nov 2017 Phase-I clinical trials in Heart failure (In volunteers) in Germany (PO)
  • 11 Nov 2017 Pharmacokinetics, pharmacodynamics and adverse events data from a phase I trial in healthy male volunteers presented at the 90th Annual Scientific Sessions of the American Heart Association (AHA-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top